Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer. - Wikidata - awgldk - TriplyDB

Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer.

Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer.

http://www.wikidata.org/entity/Q33835127

about

The broken "Off" switch in cancer signaling: PP2A as a regulator of tumorigenesis, drug resistance, and immune surveillance Protein Phosphatase 2A as a Therapeutic Target in Acute Myeloid Leukemia SIRT3 inhibits prostate cancer by destabilizing oncoprotein c-MYC through regulation of the PI3K/Akt pathway.Computer-aided targeting of the PI3K/Akt/mTOR pathway: toxicity reduction and therapeutic opportunities Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth.The role of SET/I2PP2A in canine mammary tumors.Phorbol esters in seed oil of Jatropha curcas L. (saboodam in Thai) and their association with cancer prevention: from the initial investigation to the present topics.Altered PPP2R2A and Cyclin D1 expression defines a subgroup of aggressive luminal-like breast cancer.PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer.Lithium Chloride Promotes Apoptosis in Human Leukemia NB4 Cells by Inhibiting Glycogen Synthase Kinase-3 Beta.Inhibition of Pten deficient Castration Resistant Prostate Cancer by Targeting of the SET - PP2A Signaling axis.Strategies to Inhibit Myc and Their Clinical Applicability Norcantharidin inhibits renal interstitial fibrosis by downregulating PP2Ac expression.SET antagonist enhances the chemosensitivity of non-small cell lung cancer cells by reactivating protein phosphatase 2A Zinc Finger and X-Linked Factor (ZFX) Binds to Human SET Transcript 2 Promoter and Transactivates SET Expression.Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemia.Clinical significance of cancerous inhibitor of protein phosphatase 2A in human cancers.OP449 inhibits breast cancer growth without adverse metabolic effects.All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase.Reprogramming the oncogenic response: SET protein as a potential therapeutic target in cancer.SET/I2PP2A overexpression induces phenotypic, molecular, and metabolic alterations in an oral keratinocyte cell line.PROTOCADHERIN 7 Acts through SET and PP2A to Potentiate MAPK Signaling by EGFR and KRAS during Lung Tumorigenesis.The therapeutic effects of SET/I2PP2A inhibitors on canine melanoma.SCP1 regulates c-Myc stability and functions through dephosphorylating c-Myc Ser62.Leucine-rich repeat-containing protein 59 mediates nuclear import of cancerous inhibitor of PP2A in prostate cancer cells.Cip2a promotes cell cycle progression in triple-negative breast cancer cells by regulating the expression and nuclear export of p27Kip1.MYC Modulation around the CDK2/p27/SKP2 Axis MYC-dependent recruitment of RUNX1 and GATA2 on the SET oncogene promoter enhances PP2A inactivation in acute myeloid leukemia.Directional Migration in Esophageal Squamous Cell Carcinoma (ESCC) is Epigenetically Regulated by SET Nuclear Oncogene, a Member of the Inhibitor of Histone Acetyltransferase Complex.Isoliensinine induces dephosphorylation of NF-kB p65 subunit at Ser536 via a PP2A-dependent mechanism in hepatocellular carcinoma cells: roles of impairing PP2A/I2PP2A interaction.SET contributes to the epithelial-mesenchymal transition of pancreatic cancer.MYC regulates ductal-neuroendocrine lineage plasticity in pancreatic ductal adenocarcinoma associated with poor outcome and chemoresistance.PP2A as the Main Node of Therapeutic Strategies and Resistance Reversal in Triple-Negative Breast Cancer.Therapeutic Targeting of PP2A.Functional importance of PP2A regulatory subunit loss in breast cancer.Loss of protein phosphatase 2A regulatory subunit B56δ promotes spontaneous tumorigenesis in vivo.Upregulation of the oncoprotein SET determines poor clinical outcomes in hepatocellular carcinoma and shows therapeutic potential.Effect of matrine against breast cancer by downregulating the vascular endothelial growth factor via the Wnt/β-catenin pathway.Small molecule activators of protein phosphatase 2A for the treatment of castration-resistant prostate cancer.

P2860

Q26739246-E3929387-0639-4712-BAEF-281598316461 Q26752430-98B173D9-330A-453D-B1FA-BA40E56DCEE7 Q27341759-A2423073-6993-4590-9B4A-02CD7DE2602C Q28397537-722BF129-257E-4D24-91BB-8E0860453907 Q30252408-F3A9DF53-6634-4187-8677-8A9B1360485B Q33842870-000F5107-DF4C-443E-AD94-A530B4BA1B02 Q33890604-D3BBDA8C-95C3-43BC-BD54-7A684B90A713 Q35538100-F1D39D4D-E1EA-4926-91FB-46D54AB34029 Q35552005-1675E58E-808D-419F-A168-71C6CF30E59C Q36020877-31130DD3-8934-45A1-B901-B07826BC84D8 Q36189756-8EAB0D5A-6210-4A59-AF5A-FF1F5A56F442 Q36275673-AC110394-5F5E-4631-A76C-F95539D0B40A Q36303678-85F923AE-E6DD-49F2-9F44-60C8BA21A6CE Q36420214-6458D969-5579-4245-9DA9-8F81B2E6323E Q36729492-EC5142B5-F1A8-4572-918A-086DB7E31D0F Q37377505-A91392A4-DDDC-45C5-B7EE-35AE1B672522 Q37708933-51279F54-D26D-4262-8E9D-C5196D44C34F Q38335027-9C33275F-CF3F-48CC-B314-4BA7F375631F Q38613399-213C1E00-3132-46B3-9061-D0623B68583B Q38617799-172CB537-F351-433B-BCA2-5ACDCEC86CD1 Q38678579-C8B9C441-8179-4781-96B8-86F7E74EC730 Q38699543-A361F88C-5B15-411B-8991-2EF175FAD46F Q38732488-C4E8EF1B-F507-4BD8-9410-BB1A1B8D903D Q38865301-0737E844-7551-4F52-B139-A570D07DFA1C Q38884675-6AEA9E63-6CC7-4DB3-ACC1-115C1CD4ECDC Q38891984-BAB58A59-32C8-4338-B0CA-DBDBCFA564EB Q39330291-2F68F3E1-74DB-4486-A14A-9E67B5BA550B Q39406924-F235D293-ECF7-4D57-9D2E-D455091117EC Q41553595-7D5FF4AE-5027-469A-B0A2-08B004099C6B Q41667220-EF8D3C4D-39B6-4701-B567-50565FEBF885 Q41976132-7618C973-7412-4AD8-B642-C371186A4694 Q42100343-08785088-E7B4-4C5C-9CF0-9EBF373570A5 Q47111931-76541F8B-D654-4EEA-9026-E2E2437ED61A Q47271622-80E898B7-6014-4468-9199-D284C0C311A5 Q47436859-11BCC647-4AA4-4030-9AF2-1F9AB0557180 Q47571869-D936303C-DEBC-4CAC-A971-7CD2E981B4B0 Q47716673-CA20C01F-7FFF-4DBF-8F72-F3EEB5C18D34 Q48064023-88707772-7773-4BAC-9AE2-4528CAE826C4 Q50045926-B6381EF2-ECD9-42AC-95AE-88C426058DA6 Q50091777-0A21C721-4C3D-4D0D-874D-65596F08DE96

P2860

Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer.

http://www.wikidata.org/entity/Q33835127

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer.

@ast

Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer.

@en

type

label

Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer.

@ast

Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer.

@en

prefLabel

Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer.

@ast

Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer.

@en

P1433

Q33835127-40880105-BF3E-4D78-9D22-480546105EF1

P1476

Q33835127-21E99187-33A5-4725-8A6B-BBDF18D94CD0

P2093

Q33835127-02CB25C9-2502-4190-A97C-2EC21B6A89B1

Q33835127-6FEA101B-AFBD-41A5-B41B-DB6D24891571

Q33835127-7EC638FF-AD12-48A9-B91F-3A196967273A

Q33835127-842A456C-6902-4BF9-991C-0CEFC0C01971

Q33835127-AC476356-54D7-4CDC-A95A-BD20A3835FBE

Q33835127-D8EA67A5-7C0C-4746-9FFC-D2C338652859

Q33835127-E1755917-9289-4609-96AE-B0CE44E2ECB2

Q33835127-FE46A4E6-4C70-48B4-8B05-078C1EF6E1E3

P2860

Q33835127-10AB3CDB-2CB5-43D4-B2B5-3AB9AED57E5D

Q33835127-1B3213C4-82C9-47BD-BF65-789B889F90F7

Q33835127-1DA59AF1-7C81-46D6-B73A-53A06C84A350

Q33835127-1DE2F4B2-7132-4D0B-81C4-685EE02213F1

Q33835127-2E569DF4-07F7-41A4-9537-4FD0DEC606E8

Q33835127-38A0DFE7-988E-439D-AFE6-F49A2DC61597

Q33835127-3E70825F-CC20-48A4-AB8A-42E31B8AA119

Q33835127-44EEADFA-CD43-4A8C-B959-9E1D1D9AB44F

Q33835127-56038D69-0463-4535-B0FC-CFCC9573CB9C

Q33835127-5A119426-F851-44C1-BCD6-78A90B8C0E5C

P304

Q33835127-620D0B20-E646-4371-B8AB-9B021568E30B

P31

Q33835127-31C2620B-3981-4B88-88BF-54045D03B773

P356

Q33835127-19AD97A8-5E56-4E3A-877D-A147F2D6F4D3

P407

Q33835127-C70DC866-DA7C-46AA-89C6-F655C4E67628

P433

Q33835127-C7EFBDA0-08DE-4A22-BAC0-8972105F6443

P478

Q33835127-7F9A5909-8318-48D0-A059-48D7EE0BBB14

P50

Q33835127-23E467C4-DF38-47D1-8187-B7E65CD8DF94

P577

Q33835127-1B18B7FF-CCB5-4D24-A94C-2E3B127FCA83

P5875

Q33835127-7966A679-4088-43C2-821C-36422397865C

P698

Q33835127-35E5B528-785A-48BE-8818-91E9D4CAEA73

P932

Q33835127-B079C4E1-E00B-4129-B633-2446099FF638

P356

PNAS.1317630111

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer.

@en

P2093

Amy S Farrell

http://www.w3.org/2001/XMLSchema#string

Carl Pelz

http://www.w3.org/2001/XMLSchema#string

Colin J Daniel

http://www.w3.org/2001/XMLSchema#string

Dale J Christensen

http://www.w3.org/2001/XMLSchema#string

Ellen M Langer

http://www.w3.org/2001/XMLSchema#string

Jessica Oddo

http://www.w3.org/2001/XMLSchema#string

Mahnaz Janghorban

http://www.w3.org/2001/XMLSchema#string

Rosalie C Sears

http://www.w3.org/2001/XMLSchema#string

P2860

The Axin1 scaffold protein promotes formation of a degradation complex for c-Myc

Identification of PP2A complexes and pathways involved in cell transformation

CIP2A inhibits PP2A in human malignancies

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

PID: the Pathway Interaction Database

Phosphorylation by Cdk2 is required for Myc to repress Ras-induced senescence in cotransformation.

MYC regulation of a "poor-prognosis" metastatic cancer cell state.

Mechanistic insight into Myc stabilization in breast cancer involving aberrant Axin1 expression

A tumor suppressor role for PP2A-B56alpha through negative regulation of c-Myc and other key oncoproteins.

Pin1 regulates the dynamics of c-Myc DNA binding to facilitate target gene regulation and oncogenesis.

P304

9157-9162

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1317630111

http://www.w3.org/2001/XMLSchema#string

P407

P433

25

http://www.w3.org/2001/XMLSchema#string

P478

111

http://www.w3.org/2001/XMLSchema#string

P50

Brittany L Allen-Petersen

P577

2014-06-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263098955

http://www.w3.org/2001/XMLSchema#string

P698

24927563

http://www.w3.org/2001/XMLSchema#string

P932

4078832

http://www.w3.org/2001/XMLSchema#string